Stem-cell Transplantation May Improve Overall Survival of Patients With Relapsed MM

Share this content:
Salvage autologous stem-cell transplantation (ASCT) may improve overall survival (OS) of patients with relapsed multiple myeloma.
Salvage autologous stem-cell transplantation (ASCT) may improve overall survival (OS) of patients with relapsed multiple myeloma.

Salvage autologous stem-cell transplantation (ASCT) may improve the overall survival (OS) of patients with relapsed multiple myeloma treated with an initial ASCT, according to the overall results of a study recently published in The Lancet Haematology.1

Investigators of Myeloma X, a multicenter, randomized, open-label, phase 3 trial, found that ASCT improved time to disease progression, in contrast to oral cyclophosphamide, for patients with relapsed multiple myeloma. OS rates, however, were not initially published.

The authors write that of 89 patients assigned to receive salvage ASCT and high-dose melphalan, median OS was 67 months; median OS for the oral cyclophosphamide group, to which 85 patients were assigned, was 52 months (P = .0169).

At extended follow-up, 7 patients in the ASCT group had second primary malignancies; this was observed in only 5 patients in the oral cyclophosphamide group.

RELATED: Significant Variations May Exist in Treatment Practices for Multiple Myeloma

The authors conclude that salvage ASCT improves OS of patients with relapsed multiple myeloma, though ASCT should be performed during consolidation of re-induction treatment. Delay of ASCT treatment is not as advantageous.

No further adverse events were reported at extended follow-up.

Reference

1. Cook G, Ashcroft AJ, Cairns DA, et al. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Lancet Haematol. 3 Jul 2016. doi: 10.1016/S2352-3026(16)30049-7 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters